Prostate-specific antigen (PSA) screening aims to identify men who may harbor potentially lethal prostate cancer, and those with high PSA results often require more extensive (and expensive) diagnostic testing to establish a diagnosis. New research reveals that the out-of-pocket costs for such additional tests are substantial, common, and rising. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.
Prostate-specific antigen (PSA) screening aims to identify men who may harbor potentially lethal prostate cancer, and those with high PSA results often require more extensive (and expensive) diagnostic testing to establish a diagnosis. New research reveals that the out-of-pocket costs for such additional tests are substantial, common, and rising. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.
Abnormal screening tests (i.e., elevated PSA) warrant additional testing involving magnetic resonance imaging and/or prostate biopsies. High out-of-pocket costs for these tests—including copayment, coinsurance, and deductibles—may not only place a substantial burden on patients, but also may deter patients from going through with recommended screening.
To investigate the extent of such financial burdens, researchers analyzed information on 3,075,841 US privately insured men ages 55–69 years old who underwent PSA screening in 2010–2020. Among these men, 91,850 had a second PSA test and an elevated PSA, of which 40,329 (43.9%) underwent subsequent diagnostic testing.
Among the men who underwent subsequent testing, more than 75% experienced out-of-pocket costs. The median out-of-pocket costs rose substantially over the years of the study for patients undergoing biopsy only ($79 to $214), imaging only ($81 to $490), and imaging plus biopsy ($353 to $620).
In 2023, the American Cancer Society published a statement asserting that cancer screening is a multistep process, stressing that payers must eliminate out-of-pocket costs for all necessary diagnostic tests. “In the context of prostate cancer, this means that insurance companies should provide full coverage for imaging, prostate biopsy, and other recommended testing, if indicated by an abnormal prostate cancer screening test,” said lead author Arnav Srivastava, MD, MPH, of the University of Michigan, Ann Arbor. “We have seen this strategy successfully implemented in colorectal cancer screening, as part of a new addition to the Affordable Care Act. Thus, we recommend that policymakers and insurance companies offer full coverage for testing throughout the screening pathway and eliminate cost-sharing for patients.”
This study was led by Dr. Arnav Srivastava, Ms. Anca Tilea, Dr. David D. Kim, Dr. Vanessa K. Dalton, and Dr. A. Mark Fendrick.
Additional information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. A free abstract of this article will be available via the CANCER Newsroom upon online publication. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout, newsroom@wiley.com
Full Citation:
“Out-of-Pocket Costs for Diagnostic Testing Following Abnormal Prostate Cancer Screening Among Privately Insured Men.” Arnav Srivastava, Anca Tilea, David D. Kim, Vanessa K. Dalton, and A. Mark Fendrick. CANCER; Published Online: July 15, 2024 (DOI: 10.1002/cncr.35392)
Author Contact: Kara Gavin at kegavin@med.umich.edu
About the Journal
CANCER is a peer-reviewed publication of the American Cancer Society integrating scientific information from worldwide sources for all oncologic specialties. The objective of CANCER is to provide an interdisciplinary forum for the exchange of information among oncologic disciplines concerned with the etiology, course, and treatment of human cancer. CANCER is published on behalf of the American Cancer Society by Wiley and can be accessed online. Follow CANCER on X @JournalCancer and Instagram @ACSJournalCancer, and stay up to date with the American Cancer Society Journals on LinkedIn.
About Wiley
Wiley is a knowledge company and a global leader in research, publishing, and knowledge solutions. Dedicated to the creation and application of knowledge, Wiley serves the world’s researchers, learners, innovators, and leaders, helping them achieve their goals and solve the world’s most important challenges. For more than two centuries, Wiley has been delivering on its timeless mission to unlock human potential. Visit us at Wiley.com. Follow us on Facebook, X, LinkedIn and Instagram.
Journal
Cancer
Article Title
Out-of-Pocket Costs for Diagnostic Testing Following Abnormal Prostate Cancer Screening Among Privately Insured Men
Article Publication Date
15-Jul-2024
